Calidi Biotherapeutics, Inc.
CLDI
$1.59
$0.053.25%
AMEX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -39.32% | -4.66% | -12.56% | -14.81% | -34.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.29% | 10.93% | -3.41% | -1.87% | -25.03% |
| Operating Income | 17.29% | -10.93% | 3.41% | 1.87% | 25.03% |
| Income Before Tax | 18.88% | 2.03% | -1.99% | 0.03% | 29.94% |
| Income Tax Expenses | 33.33% | -166.67% | 1,100.00% | -50.00% | -25.00% |
| Earnings from Continuing Operations | 18.85% | 2.15% | -2.21% | 0.10% | 29.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -94.12% | 113.33% | -- | -- |
| Net Income | 17.61% | 1.00% | -1.88% | 0.90% | 30.99% |
| EBIT | 17.29% | -10.93% | 3.41% | 1.87% | 25.03% |
| EBITDA | 19.43% | -15.00% | 3.62% | 3.28% | 29.80% |
| EPS Basic | 80.60% | 82.30% | 71.55% | 88.14% | 90.94% |
| Normalized Basic EPS | 81.80% | 81.08% | 86.52% | 84.77% | 91.03% |
| EPS Diluted | 80.60% | 82.30% | 71.55% | 88.14% | 90.94% |
| Normalized Diluted EPS | 81.80% | 81.08% | 86.52% | 84.77% | 91.03% |
| Average Basic Shares Outstanding | 356.63% | 459.17% | 651.72% | 546.76% | 662.70% |
| Average Diluted Shares Outstanding | 356.63% | 459.17% | 651.72% | 546.76% | 662.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |